SCHEMBL13660737

SCHEMBL13660737

CCOC(=O)CC1COc2ccccc2N1S(=O)(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.53
HTT P42858 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 2/20 0.42
USP2 O75604 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
POLB P06746 2/20 0.40
MAPT P10636 2/20 0.39
GAA P10253 1/20 0.39
BDKRB1 P46663 1/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295681 0.87 NPC1 (0.48) NPC1HTTL3MBTL1SMN1; SMN2NPSR1
SCHEMBL12339968 0.79 NPC1 (0.65) NPC1HTTL3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL4293128 0.70 NPC1 (0.34) NPC1POLBBDKRB1
SCHEMBL17363749 0.70 L3MBTL1 (0.52) HTTL3MBTL1SMN1; SMN2ALDH1A1USP2
SCHEMBL17363743 0.69 L3MBTL1 (0.48) HTTL3MBTL1SMN1; SMN2ALDH1A1USP2
SCHEMBL8543224 0.68 LMNA (0.65) NPC1L3MBTL1SMN1; SMN2ALDH1A1CYP3A4
SCHEMBL643338 0.67 HTT (1.00) HTTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL10246396 0.67 NPC1 (0.45) NPC1L3MBTL1SMN1; SMN2ALDH1A1NPSR1
SCHEMBL23390426 0.67 MAPT (0.54) NPC1HTTSMN1; SMN2ALDH1A1NPSR1
SCHEMBL29948811 0.67 MAPT (0.54) NPC1HTTSMN1; SMN2ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318769-B2 Substituted sulfonamide compounds GRUENETHAL GMBH (DE) 2012-11-27 US disclosed
US-8318769-B2 Substituted sulfonamide compounds GRUENETHAL GMBH (DE) 2012-11-27 US disclosed
US-20090264400-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-22 US disclosed
US-20090264400-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-22 US disclosed
WO-2009124733-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264400-A1 Substituted Sulfonamide Compounds BDKRB1, BDKRB2, TRPV1 NPC1 2705/4885HTT 3247/4885L3MBTL1 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.